This inventor holds 1 USPTO granted patent. Top assignee: Kyoto University. Active years: 2017.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2017
Title: Innovations in Prostate Cancer Testing by Jun Utsumi
Introduction
Jun Utsumi is an accomplished inventor based in Kyoto, Japan. He has made significant contributions to the field of medical diagnostics, particularly in the area of prostate cancer testing. His innovative approach focuses on noninvasive methods that enhance the accuracy of cancer detection.
Latest Patents
Utsumi holds a patent for a novel urinary biomarker used in tests for prostate cancer. This groundbreaking method allows for noninvasive testing that is more accurate than traditional methods. By analyzing urine samples from both prostate cancer patients and individuals free of the disease, Utsumi and his team discovered specific urinary peptides that serve as indicators for prostate cancer. These peptides facilitate various tests, including the detection of prostate cancer, differentiation between prostate cancer and benign prostatic hyperplasia, monitoring therapeutic effects, and tracking postoperative recurrence. He has 1 patent related to this innovative work.
Career Highlights
Utsumi's career is marked by his dedication to improving cancer diagnostics. His work at Kyoto University has positioned him as a leading figure in the research community. His innovative methods have the potential to transform how prostate cancer is diagnosed and monitored, ultimately improving patient outcomes.
Collaborations
Utsumi has collaborated with notable colleagues, including Kazuharu Shimizu and Osamu Ogawa. Their combined expertise has contributed to the advancement of research in prostate cancer diagnostics.
Conclusion
Jun Utsumi's contributions to prostate cancer testing exemplify the impact of innovative research in medical diagnostics. His work not only enhances the accuracy of cancer detection but also paves the way for more effective patient management strategies.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
